TY - JOUR
T1 - The membrane-linked adaptor FRS2β fashions a cytokine-rich inflammatory microenvironment that promotes breast cancer carcinogenesis
AU - Takeuchi, Yasuto
AU - Kimura, Natsuko
AU - Murayama, Takahiko
AU - Machida, Yukino
AU - Iejima, Daisuke
AU - Nishimura, Tatsunori
AU - Terashima, Minoru
AU - Wang, Yuming
AU - Li, Mengjiao
AU - Sakamoto, Reiko
AU - Yamamoto, Mizuki
AU - Itano, Naoki
AU - Inoue, Yusuke
AU - Ito, Masataka
AU - Yoshida, Nobuaki
AU - Inoue, Jun Ichiro
AU - Akashi, Koichi
AU - Saya, Hideyuki
AU - Fujita, Koji
AU - Kuroda, Masahiko
AU - Kitabayashi, Issay
AU - Voon, Dominic
AU - Suzuki, Takeshi
AU - Tojo, Arinobu
AU - Gotoh, Noriko
N1 - Funding Information:
ACKNOWLEDGMENTS. We are grateful to M. Watanabe (Institute of Medical Science, The University of Tokyo) for technical support and to H. Nakauchi, Y. Ishii, and A. Fujita (Institute of Medical Science, The University of Tokyo) for their help with flow cytometry. We are thankful to ChemoCentryx, Inc. for kindly providing CCX771 and to K. Umezawa (Aichi Medical University) for kindly providing DHMEQ. This work was supported in part by an Extramural Collaborative Research Grant from the Cancer Research Institute at Kanazawa University, the Ministry of Education, Culture, Sports, Science, and Technology KAKENHI Grant Number. 22130009 and 20H05029; the Japan Soceity for Promotion of Science KAKENHI Grant Number. JP17K19587, JP18H02679, JP19K22557, and JP21H02761; and a research grant from AMED Project for Cancer Research and Therapeutic Evolution (Grant Number. 19193063 and 21446781) to N.G.
Funding Information:
We are grateful to M. Watanabe (Institute of Medical Science, The University of Tokyo) for technical support and to H. Nakauchi, Y. Ishii, and A. Fujita (Institute of Medical Science, The University of Tokyo) for their help with flow cytometry. We are thankful to ChemoCentryx, Inc. for kindly providing CCX771 and to K. Umezawa (Aichi Medical University) for kindly providing DHMEQ. This work was supported in part by an Extramural Collaborative Research Grant from the Cancer Research Institute at Kanazawa University, the Ministry of Education, Culture, Sports, Science, and Technology KAKENHI Grant Number. 22130009 and 20H05029; the Japan Soceity for Promotion of Science KAKENHI Grant Number. JP17K19587, JP18H02679, JP19K22557, and JP21H02761; and a research grant from AMED Project for Cancer Research and Therapeutic Evolution (Grant Number. 19193063 and 21446781) to N.G.
Publisher Copyright:
© 2021 National Academy of Sciences. All rights reserved.
PY - 2021/10/26
Y1 - 2021/10/26
N2 - Although it is held that proinflammatory changes precede the onset of breast cancer, the underlying mechanisms remain obscure. Here, we demonstrate that FRS2β, an adaptor protein expressed in a small subset of epithelial cells, triggers the proinflammatory changes that induce stroma in premalignant mammary tissues and is responsible for the disease onset. FRS2β deficiency in mouse mammary tumor virus (MMTV)–ErbB2 mice markedly attenuated tumorigenesis. Importantly, tumor cells derived from MMTV-ErbB2 mice failed to generate tumors when grafted in the FRS2β-deficient premalignant tissues. We found that colocalization of FRS2β and the NEMO subunit of the IκB kinase complex in early endosomes led to activation of nuclear factor–κB (NF-κB), a master regulator of inflammation. Moreover, inhibition of the activities of the NF-κB–induced cytokines, CXC chemokine ligand 12 and insulin-like growth factor 1, abrogated tumorigenesis. Human breast cancer tissues that express higher levels of FRS2β contain more stroma. The elucidation of the FRS2β–NF-κB axis uncovers a molecular link between the proinflammatory changes and the disease onset.
AB - Although it is held that proinflammatory changes precede the onset of breast cancer, the underlying mechanisms remain obscure. Here, we demonstrate that FRS2β, an adaptor protein expressed in a small subset of epithelial cells, triggers the proinflammatory changes that induce stroma in premalignant mammary tissues and is responsible for the disease onset. FRS2β deficiency in mouse mammary tumor virus (MMTV)–ErbB2 mice markedly attenuated tumorigenesis. Importantly, tumor cells derived from MMTV-ErbB2 mice failed to generate tumors when grafted in the FRS2β-deficient premalignant tissues. We found that colocalization of FRS2β and the NEMO subunit of the IκB kinase complex in early endosomes led to activation of nuclear factor–κB (NF-κB), a master regulator of inflammation. Moreover, inhibition of the activities of the NF-κB–induced cytokines, CXC chemokine ligand 12 and insulin-like growth factor 1, abrogated tumorigenesis. Human breast cancer tissues that express higher levels of FRS2β contain more stroma. The elucidation of the FRS2β–NF-κB axis uncovers a molecular link between the proinflammatory changes and the disease onset.
KW - Breast cancer
KW - Cancer-associated fibroblasts
KW - FRS3
KW - NF-κB
KW - Premalignant inflammation
UR - http://www.scopus.com/inward/record.url?scp=85117388080&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85117388080&partnerID=8YFLogxK
U2 - 10.1073/pnas.2103658118
DO - 10.1073/pnas.2103658118
M3 - Article
C2 - 34663724
AN - SCOPUS:85117388080
SN - 0027-8424
VL - 118
JO - Proceedings of the National Academy of Sciences of the United States of America
JF - Proceedings of the National Academy of Sciences of the United States of America
IS - 43
M1 - e2103658118
ER -